183 related articles for article (PubMed ID: 36530327)
1.
Barua SA; Goswami N; Mishra N; Sawant UU; Varma AK
ACS Omega; 2022 Dec; 7(49):44772-44785. PubMed ID: 36530327
[TBL] [Abstract][Full Text] [Related]
2. Structural dynamics of clinically-reported VUS in the BARD1 ARD-BRCT region to predict the molecular basis of alterations.
Barua SA; Choudhary RK; Gawde J; Mishra N; Varma AK
J Biomol Struct Dyn; 2024 Jul; 42(11):5475-5484. PubMed ID: 37418175
[TBL] [Abstract][Full Text] [Related]
3. Biophysical evaluation to categorize pathogenicity of cancer-predisposing mutations identified in the BARD1 BRCT domain.
Choudhary RK; Siddiqui MQ; Gadewal N; Kumar NS; Kuligina ES; Varma AK
RSC Adv; 2018 Sep; 8(59):34056-34068. PubMed ID: 35548793
[TBL] [Abstract][Full Text] [Related]
4. Classification of VUS and unclassified variants in
Sinha S; Wang SM
Comput Struct Biotechnol J; 2020; 18():723-736. PubMed ID: 32257056
[TBL] [Abstract][Full Text] [Related]
5. Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Choudhary RK; Vikrant ; Siddiqui QM; Thapa PS; Raikundalia S; Gadewal N; Kumar NS; Hosur MV; Varma AK
J Biomol Struct Dyn; 2016 Jul; 34(7):1533-44. PubMed ID: 26307947
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the BARD1 BRCT domains.
Birrane G; Varma AK; Soni A; Ladias JA
Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
[TBL] [Abstract][Full Text] [Related]
8. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
[TBL] [Abstract][Full Text] [Related]
9. Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
Ayi TC; Tsan JT; Hwang LY; Bowcock AM; Baer R
Oncogene; 1998 Oct; 17(16):2143-8. PubMed ID: 9798686
[TBL] [Abstract][Full Text] [Related]
10. Functional and structural analysis of C-terminal BRCA1 missense variants.
Quiles F; Fernández-Rodríguez J; Mosca R; Feliubadaló L; Tornero E; Brunet J; Blanco I; Capellá G; Pujana MÀ; Aloy P; Monteiro A; Lázaro C
PLoS One; 2013; 8(4):e61302. PubMed ID: 23613828
[TBL] [Abstract][Full Text] [Related]
11. The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
Billing D; Horiguchi M; Wu-Baer F; Taglialatela A; Leuzzi G; Nanez SA; Jiang W; Zha S; Szabolcs M; Lin CS; Ciccia A; Baer R
Mol Cell; 2018 Oct; 72(1):127-139.e8. PubMed ID: 30244837
[TBL] [Abstract][Full Text] [Related]
12. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
Edwards RA; Lee MS; Tsutakawa SE; Williams RS; Nazeer I; Kleiman FE; Tainer JA; Glover JN
Biochemistry; 2008 Nov; 47(44):11446-56. PubMed ID: 18842000
[TBL] [Abstract][Full Text] [Related]
13. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
14. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
[TBL] [Abstract][Full Text] [Related]
15. Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Thanassoulas A; Nomikos M; Theodoridou M; Stavros P; Mastellos D; Nounesis G
Int J Biol Macromol; 2011 Oct; 49(3):297-304. PubMed ID: 21600917
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity.
Adamovich AI; Banerjee T; Wingo M; Duncan K; Ning J; Martins Rodrigues F; Huang KL; Lee C; Chen F; Ding L; Parvin JD
PLoS Genet; 2019 Mar; 15(3):e1008049. PubMed ID: 30925164
[TBL] [Abstract][Full Text] [Related]
17. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
Rodriguez M; Yu X; Chen J; Songyang Z
J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
[TBL] [Abstract][Full Text] [Related]
18. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance.
Langerud J; Jarhelle E; Van Ghelue M; Ariansen SL; Iversen N
Hum Genomics; 2018 Nov; 12(1):51. PubMed ID: 30458859
[TBL] [Abstract][Full Text] [Related]
19. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
[TBL] [Abstract][Full Text] [Related]
20. BRCA1-dependent and independent functions of BARD1.
Irminger-Finger I; Leung WC
Int J Biochem Cell Biol; 2002 Jun; 34(6):582-7. PubMed ID: 11943588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
